OppenheimerFunds Inc. increased its holdings in Catalent Inc (NYSE:CTLT) by 38.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 324,062 shares of the company’s stock after purchasing an additional 90,650 shares during the quarter. OppenheimerFunds Inc. owned 0.24% of Catalent worth $13,313,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also recently made changes to their positions in the company. Zions Bancorporation bought a new stake in Catalent during the third quarter worth about $100,000. First Bank & Trust raised its holdings in Catalent by 54.2% in the fourth quarter. First Bank & Trust now owns 3,764 shares of the company’s stock worth $155,000 after buying an additional 1,323 shares during the last quarter. CAPROCK Group Inc. purchased a new position in Catalent in the fourth quarter worth about $203,000. Eagle Boston Investment Management Inc. purchased a new position in Catalent in the third quarter worth about $216,000. Finally, Trexquant Investment LP purchased a new position in Catalent in the third quarter worth about $257,000. 99.89% of the stock is currently owned by institutional investors and hedge funds.
In related news, SVP William Downie sold 9,082 shares of Catalent stock in a transaction on Thursday, March 8th. The shares were sold at an average price of $41.80, for a total value of $379,627.60. Following the sale, the senior vice president now owns 46,986 shares of the company’s stock, valued at approximately $1,964,014.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.70% of the stock is currently owned by company insiders.
Catalent Inc (NYSE:CTLT) traded up $0.08 during mid-day trading on Wednesday, reaching $42.56. 359,436 shares of the company were exchanged, compared to its average volume of 933,992. Catalent Inc has a one year low of $27.48 and a one year high of $47.87. The company has a quick ratio of 1.78, a current ratio of 2.22 and a debt-to-equity ratio of 2.66. The firm has a market cap of $5,798.03, a PE ratio of 74.32, a PEG ratio of 2.49 and a beta of 1.54.
Catalent (NYSE:CTLT) last posted its quarterly earnings results on Monday, February 5th. The company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.10. The company had revenue of $606.30 million during the quarter, compared to analyst estimates of $565.05 million. Catalent had a net margin of 3.03% and a return on equity of 23.85%. Catalent’s revenue for the quarter was up 25.3% compared to the same quarter last year. During the same period last year, the firm posted $0.27 EPS. sell-side analysts anticipate that Catalent Inc will post 1.53 earnings per share for the current year.
A number of equities analysts have weighed in on CTLT shares. Zacks Investment Research lowered shares of Catalent from a “buy” rating to a “hold” rating in a research report on Friday, March 9th. Stephens lowered shares of Catalent from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, February 6th. Bank of America upped their price target on shares of Catalent from $47.00 to $49.00 and gave the company a “buy” rating in a research note on Tuesday, February 6th. ValuEngine raised shares of Catalent from a “hold” rating to a “buy” rating in a research note on Wednesday, February 7th. Finally, Royal Bank of Canada set a $48.00 target price on shares of Catalent and gave the company a “buy” rating in a research note on Monday, February 5th. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Catalent has a consensus rating of “Buy” and a consensus target price of $45.40.
COPYRIGHT VIOLATION WARNING: This story was reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.thelincolnianonline.com/2018/03/14/oppenheimerfunds-inc-has-13-31-million-position-in-catalent-inc-ctlt.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.